|国家科技期刊平台
首页|期刊导航|中国医学创新|肝细胞癌过继细胞疗法研究进展

肝细胞癌过继细胞疗法研究进展OA

Research Progress of Adoptive Cell Therapy for Hepatocellular Carcinoma

中文摘要英文摘要

肝细胞癌是严重威胁人类生存的一类疾病,中国肝细胞癌死亡率居世界第三.由于肝细胞癌发病早期无特异性症状,晚期的治疗方案又存在复发率高等的种种弊端,因此寻找行之有效的治疗新方法迫在眉睫.过继细胞疗法是一种细胞免疫疗法,在肝脏多样化和复杂的免疫微环境中,通过结合肿瘤特异性抗原或是非特异性的调节免疫平衡,过继细胞疗法在肝细胞癌的治疗中逐渐发挥出优势.在这篇综述中我们阐述了肝细胞癌靶向治疗常用生物标志物的形态结构及信号通路,探讨总结了近年来过继细胞疗法治疗肝细胞癌的研究手段及取得的临床效果,并对接下来的研究方向进行了展望.

Hepatocellular carcinoma is a kind of disease that seriously threatens human survival.The mortality of hepatocellular carcinoma in China is the third in the world.Because there are no specific symptoms in the early stage of hepatocellular carcinoma,and the treatment scheme in the late stage has various disadvantages such as high recurrence rate,it is urgent to find effective new treatment methods.Adoptive cell therapy is a kind of cellular immunotherapy.In the diversified and complex immune microenvironment of the liver,adoptive cell therapy gradually plays an advantage in the treatment of hepatocellular carcinoma by combining tumor specific antigen or non-specific regulation of immune balance.In this review,we describe the morphological structures and signaling pathways of common biomarkers for targeted therapy of hepatocellular carcinoma,and discusses and summarizes the research methods and clinical effects of adoptive cell therapy for hepatocellular carcinoma in recent years,and looks forward to the next research direction.

赫丽杰;李婷婷;张宇;李景圆;荣耀星;王大庆

辽宁省人民医院肿瘤科 辽宁 沈阳 110013沈阳汇智细胞产业技术创新研究院有限公司 辽宁 沈阳 100196沈阳细胞治疗工程技术研发中心有限公司 辽宁 沈阳 100196

肝细胞癌生物标志物自然杀伤细胞T细胞受体嵌合抗原受体T细胞

Hepatocellular carcinomaBiomarkerNatural killer cellT cell receptorChimeric antigen receptor T cell

《中国医学创新》 2024 (009)

173-180 / 8

2020年度沈阳市科学技术计划-公共卫生研发专项项目(20-205-4-012)

10.3969/j.issn.1674-4985.2024.09.039

评论